# A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

> **NCT06878248** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Calibr, a division of Scripps Research** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer Metastatic
- Locally Advanced Breast Cancer (LABC)
- Malignant Neoplasm of Breast
- Triple Negative Breast Cancer (TNBC)
- Hormone Receptor-Positive Breast Cancer
- HER2 + Breast Cancer

## Interventions

- **BIOLOGICAL:** Two Component Product CLBR001 + ABBV-461

## Key facts

- **NCT ID:** NCT06878248
- **Lead sponsor:** Calibr, a division of Scripps Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06878248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06878248, "A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06878248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*